Key highlights
- Phase I trial of AK1940 (peptide TNFR1 antagonist) began in Japan on April 19, 2026 to assess PK, safety and tolerability of single and multiple subcutaneous doses in healthy volunteers.
- AK1940 was discovered through joint research with PeptiDream and selectively targets tumor necrosis factor receptor 1 (TNFR1).
- Preclinical studies completed successfully and showed activity in animal models of inflammatory disease.
- Asahi Kasei Therapeutics is conducting the trial and will independently advance AK1940's development.
Phase I trial
Asahi Kasei Therapeutics initiated a Phase I clinical trial of AK1940 in Japan on April 19, 2026; the study will evaluate pharmacokinetics, safety and tolerability of single and multiple subcutaneous doses in healthy volunteers.
Compound profile
AK1940 is a peptide-based, selective tumor necrosis factor receptor 1 (TNFR1) antagonist intended to modulate immune responses associated with chronic inflammation.
Discovery and preclinical data
The candidate was discovered through joint research with PeptiDream and completed preclinical studies that showed activity in animal models of inflammatory disease.
Development
Asahi Kasei Therapeutics is conducting the trial and will independently advance AK1940’s clinical development.
